(Reuters) – The U.S. government will consider opportunities to “bring greater transparency” for the Medicare drug price negotiation program under President Donald Trump’s administration, a federal health agency said on Wednesday.
The price negotiation process was established under former President Joe Biden’s signature Inflation Reduction Act (IRA) in 2022.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Varun H K)
Comments